About: Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus
Creator	Trybala, Edward Watterson, Daniel Carroll, Miles Buttigieg, Karen Ferro, Vito Young, Paul Khromykh, Alexander Lima, Marcelo Skidmore, Mark Tree, Julia Yates, Edwin Fernig, David Mycroft-West, Courtney Turnbull, Jeremy Amarilla, Alberto Modhiran, Naphak Setoh, Yin Bergstrom, Tomas Chhabra, Mohit Coombes, Naomi Dredge, Keith Gandhi, Neha Guimond, Scott Hammond, Edward Jun, De Nystrom, Kristina Said, Joanna Sng, Julian Su, Dunhao
source	BioRxiv
abstract	A major global effort is currently ongoing to search for therapeutics and vaccines to treat or prevent infection by the SARS-CoV-2 virus. Repurposing existing entities is one attractive approach. The heparan sulfate mimetic pixatimod is a clinical-stage synthetic sulfated compound that is a potent inhibitor of the glycosidase heparanase, and has known anti-cancer, anti-inflammatory and also antiviral properties. Here we show that pixatimod binds directly to the SARS-CoV-2 spike protein S1 receptor binding domain (RBD) and alters its conformation. Notably, this site overlaps with the known ACE2 binding site in the S1 RBD. We find that pixatimod inhibits binding of recombinant S1 RBD to Vero cells which express the ACE2 receptor. Moreover, in assays with three different isolates of live SARS-CoV-2 virus we show that pixatimod effectively inhibits viral infection of Vero cells. Importantly, its potency is well within its safe therapeutic dose range. These data provide evidence that pixatimod is a potent antiviral agent against SARS-CoV-2. Together with its other known activities this provides a strong rationale for its clinical investigation as a new multimodal therapeutic for the current COVID-19 pandemic.
has issue date	2020-06-24(xsd:dateTime)
bibo:doi	10.1101/2020.06.24.169334
has license	biorxiv
sha1sum (hex)	6f0589b1a36d2f5dc3de1b1d64543da280c6ad9b
schema:url	https://doi.org/10.1101/2020.06.24.169334
resource representing a document's title	Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus
schema:publication	bioRxiv
resource representing a document's body	covid:6f0589b1a36d2f5dc3de1b1d64543da280c6ad9b#body_text
is schema:about of	named entity 'isolates' named entity 'sulfated' named entity 'inhibits' named entity 'synthetic' named entity 'receptor' named entity 'heparan sulfate' named entity 'CURRENT' named entity 'RBD' named entity 'Vero' named entity 'RBD' named entity 'ongoing' named entity 'inhibitor' named entity 'binding' named entity 'range' named entity 'heparan sulfate' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'assays' named entity 'potent' named entity 'anti-cancer' named entity 'viral infection' named entity 'infection' named entity 'spike protein' named entity 'COVID-19 pandemic' named entity 'clinical investigation' named entity 'vaccines' named entity 'receptor binding domain' named entity 'Vero' named entity 'therapeutic range' named entity 'viruses' named entity 'Heparin' named entity 'anti-viral' named entity 'enterocytes' named entity 'SARS-CoV-2 virus' named entity 'low molecular weight' named entity 'spike protein' named entity 'prophylaxis' named entity 'TCID50' named entity 'COVID' named entity 'free energy of binding' named entity 'SARS-CoV-2' named entity 'clone' named entity 'RMSD' named entity 'PBS' named entity 'free energy of binding' named entity 'viruses' named entity 'CO2' named entity 'GraphPad Prism' named entity 'magnesium' named entity 'heparin' named entity 'cytopathic effects' named entity 'heparan sulfate proteoglycans' named entity 'kidney' named entity 'TMB' named entity 'molecular entity' named entity 'solvation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software